Table 1 Baseline characteristics.

From: Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study

 

Total (N = 100)

Midazolam (n = 51)

Remimazolam (n = 49)

P-value

Age, years

67 (57–75)

68 (60–75)

65 (55–74)

0.216

Sex, males

61 (61.0)

30 (58.8)

31 (63.3)

0.649

BMI, kg/m2

23.1 (20.4–24.9)

21.9 (19.8–24.0)

23.9 (21.0–25.5)

0.033

Smoking history

 Never smoker

41 (41.0)

21 (41.2)

20 (40.8)

0.717

 Ex-smoker

25 (25.0)

11 (21.6)

14 (28.6)

 Current smoker

34 (34.0)

19 (37.3)

15 (30.6)

Comorbidities

 COPD

10 (10.0)

6 (11.8)

4 (8.2)

0.741

 Asthma

4 (4.0)

2 (3.9)

2 (4.1)

1.000

 Pulmonary tuberculosis

18 (18.0)

10 (19.6)

8 (16.3)

0.669

 Interstitial lung disease

2 (2.0)

0

2 (4.1)

0.238

 Diabetes mellitus

20 (20.0)

13 (25.5)

7 (14.3)

0.161

 Hypertension

33 (33.0)

17 (33.3)

16 (21.7)

0.942

 Cardiovascular disease

12 (12.0)

5 (9.8)

7 (14.3)

0.550

 Neurologic disease

3 (3.0)

2 (3.9)

1 (2.0)

1.000

 Chronic kidney disease

1 (1.0)

1 (2.0)

0

1.000

 Chronic liver disease

1 (1.0)

0

1 (2.0)

0.490

 Malignancy

13 (13.0)

6 (11.8)

7 (14.3)

0.708

Subgroup according to procedures*

 Non-biopsy group

79 (79.0)

38 (74.5)

41 (83.7)

0.329

 Biopsy group

21 (21.0)

13 (25.5)

8 (16.3)

  1. Data are presented as medians (interquartile ranges) or numbers (%).
  2. BMI body mass index, COPD chronic obstructive pulmonary disease.
  3. *Patients who underwent non-biopsy procedures (observation alone, saline washing, or secretion suction) were defined as the non-biopsy group, whereas patients who underwent biopsy-containing procedure (endobronchial forceps biopsy with or without saline washing) were defined as the biopsy group.
Back to article page